- Home
- RDHL vs AIMD Comparison
RDHL vs AIMD Comparison
Compare RDHL & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- AIMD
- Stock Information
- Founded
- RDHL 2009
- AIMD 1984
- Country
- RDHL Israel
- AIMD United States
- Employees
- RDHL N/A
- AIMD N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- AIMD Biotechnology: Pharmaceutical Preparations
- Sector
- RDHL Health Care
- AIMD Health Care
- Exchange
- RDHL Nasdaq
- AIMD Nasdaq
- Market Cap
- RDHL 3.9M
- AIMD 16.9M
- IPO Year
- RDHL N/A
- AIMD N/A
- Fundamental
- Price
- RDHL $1.70
- AIMD $3.43
- Analyst Decision
- RDHL
- AIMD
- Analyst Count
- RDHL 0
- AIMD 0
- Target Price
- RDHL N/A
- AIMD N/A
- AVG Volume (30 Days)
- RDHL 43.1K
- AIMD 88.9K
- Earning Date
- RDHL 09-05-2025
- AIMD 11-05-2025
- Dividend Yield
- RDHL N/A
- AIMD N/A
- EPS Growth
- RDHL N/A
- AIMD N/A
- EPS
- RDHL N/A
- AIMD N/A
- Revenue
- RDHL $9,550,000.00
- AIMD $110,870.00
- Revenue This Year
- RDHL $381.91
- AIMD N/A
- Revenue Next Year
- RDHL N/A
- AIMD N/A
- P/E Ratio
- RDHL N/A
- AIMD N/A
- Revenue Growth
- RDHL 157.62
- AIMD 70.25
- 52 Week Low
- RDHL $1.06
- AIMD $2.00
- 52 Week High
- RDHL $11.70
- AIMD $5.00
- Technical
- Relative Strength Index (RSI)
- RDHL 63.39
- AIMD 49.24
- Support Level
- RDHL $1.47
- AIMD $3.30
- Resistance Level
- RDHL $1.60
- AIMD $3.61
- Average True Range (ATR)
- RDHL 0.09
- AIMD 0.26
- MACD
- RDHL 0.04
- AIMD -0.06
- Stochastic Oscillator
- RDHL 97.98
- AIMD 18.29
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.